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Exposure to ultraviolet (UV) radiation induces functional
changes in keratinocytes and immune cells that lead to skin
cancer, supported by strong epidemiological and molecular
evidence demonstrating a strong causal link between UV
exposure and all forms of skin cancer.1 In fact, it is esti-
mated that UV exposure is associated with 65% of mela-
noma cases and 90% of non-melanoma skin cancers (NMSC),
including basal cell carcinoma (BCC) and squamous cell
carcinoma (SCC).2 They account for nearly 15,000 deaths,
3.5 million new cases, and more than 3 billion dollars a year
in medical costs in the United States alone, representing a
major public health concern.3,4 While the incidence of most
other malignancies has either stabilized or declined, that of
NMSC has increased and is developing even in younger age
groups.3,5 Physicians have long promoted the use of sun-
screens and the wearing of protective apparels as primary
prevention in efforts to reduce the incidence of sun-
induced skin cancers. While these efforts are important,
studies have shown only a modest reduction in actinic
keratosis6 and SCC of the skin but no reduction in BCCs,7
thus presenting the need for targeted chemoprevention
strategies.8,9
Skin carcinogenesis by DNA damage is considered a
predominant paradigm of UV toxicity. Exposure to UV ra-
diation can activate various oncogenes while inactivating
tumor suppressor genes, resulting in DNA damage and
inappropriate survival and proliferation of keratinocytes
that harbor these damages. Moreover, increasing evidence
demonstrate that inflammatory responses by the immune
cells within the tumor microenvironment also contribute
significantly to skin tumorigenesis. Initiation and progres-
sion of skin carcinogenesis mediated by UV radiation involve
complex pathways, including those of apoptosis, prolifer-
ation, autophagy, DNA repair, checkpoint signaling, meta-
bolism, and inflammation. In this review, we highlight the
recent advances in two of these key molecular processes
that result in UV-mediated skin carcinogenesis. In partic-
ular, we will discuss 1) pathways that regulate DNA damage
repair and 2) pathways that regulate the inflammatory
process potentially leading to non-melanoma skin
carcinogenesis.
Regulation of UV-induced DNA repair
The epidermis is constantly exposed to UV radiation and
thus susceptible to DNA damage. Although contributing to
less than 1e2% of UV light from the sun, UVB (280e315 nm)
radiation is considered to be the major environmental
carcinogen that leads to skin cancer, involved in both tumor
initiation and promotion.10
Exposure to UVB results in various types of DNA damage,
mainly cyclobutane pyrimidine dimers (CPD) and 6-4 pho-
toproducts (6-4 PP), DNA strand breaks, and DNA cross-
links.11 If not repaired, this DNA damage can result in
mutations in the genome, ultimately contributing to skin
carcinogenesis.12 To maintain genomic stability, cells are
equipped with delicate DNA repair mechanisms that allow
effective response to these DNA lesions, including nucleo-
tide excision repair (NER), base excision repair (BER),mismatch repair (MMR), DNA double strand break (DSB)
repair and post replication repair (PRR).13e16
Among these DNA repair mechanisms, the nucleotide
excision repair (NER) is critically important in the repair of
CPDs and 6-4 PPs.17e20 The importance of NER in cancer
protection is perhaps best demonstrated in humans with
xeroderma pigmentosum (XP), an autosomal recessive dis-
order with defects in NER.21e23 First described in the late
1800’s, XP is manifested by exaggerated sun sensitivity and
nearly 10,000-fold increased susceptibility to UV-induced
mucocutaneous neoplasms.24 The study of XP has eluci-
dated the mechanisms essential for efficient DNA repair in
response to UV-induced DNA damages. The NER pathway
involves a number of proteins that detect, unwind, and
remove the damaged DNA. NER consists of two sub-
pathways: global genomic repair (GG-NER), which
removes DNA damage from the entire genome; and
transcription-coupled repair (TC-NER), which eliminates
lesions located on actively transcribed genes. During GG-
NER, a specific DNA repair mechanism is activated, which
involves DNA damage-binding proteins 1 and 2 (DDB1 and
DDB2) and the xeroderma pigmentosum (XP) proteins (XPA,
XPB, XPC, XPD, XPE, XPF, and XPG).17e20 There are seven
NER-deficient genetic complementation groups of XP (XP-A
to -G), and the XP group C (XPC) protein has been shown to
play an essential role in damage recognition for global
genomic NER (GG-NER). In particular, XPC functions as a key
player in damage recognition in GG-NER in protection
against UV-induced cancers, and the XPC gene is deleted or
mutated in human SCC.25 We know that XPC abundance is
critical for efficient GG-NER and thus for preventing UVB-
induced skin carcinogenesis.26,27 The regulation of XPC is
an area of active investigation and will be reviewed here.
Recent studies have demonstrated that XPC abundance is
regulated by multiple pathways critical for carcinogenesis.
For example, the tumor suppressors p53 and ARF promote
XPC expression to enhance NER.28,29 Here we focus on some
of the recent discoveries of molecular pathways that have
been implicated in XPC regulation in NER and as critical
targets of UVB radiation.PTEN
Phosphatase tensin homolog (PTEN) is well established as a
tumor suppressor gene that induces apoptosis and reduces
cell proliferation by inhibition of the PI3K/AKT pathway.
PTEN is frequently mutated, deleted, or epigenetically
silenced in many human cancers. In recent years, PTEN has
revealed itself to encompass even a broader role as a
critical factor in the regulation DNA damage repair,
including DSB repair and NER.
Shen et al demonstrated that cells deficient in PTEN
have defective DNA repair, due to downregulation of Rad51
and lack of PTEN at the centromeres.30 PTEN acts on the
chromatin and regulates Rad51 expression, which results in
reduction of spontaneous DSBs. However, Gupta et al found
that deficiency in PTEN does not lead to alterations in the
initial steps of DNA damage sensing and chromatin modifi-
cation associated with DNA DSBs.31 The discrepancy may
suggest cell-specific function of PTEN in DSB repair and
indicates the need for further investigation.
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regulation in response to UV radiation (Fig. 1). Ming et al
showed that mice with targeted PTEN downregulation in
their epidermis are predisposed to skin tumorigenesis when
exposed to low UV radiation and that PTEN was found to be
significantly downregulated in both premalignant and ma-
lignant skin lesions.32 Inhibition of PTEN reduced XPC
expression, which translated to significant reduction in the
repair of CPDs and 6-4 PPs, indicating that PTEN is required
for efficient GG-NER. Furthermore, positive regulation of
XPC by PTEN was found to be via the AKT/p38 pathway.
Nrf1
Nuclear factor erythroid 2-related factor 1 (Nrf1, also
called NFE2L1) is member of the Cap’n’ collar basic leucine
zipper (CNC-bZIP) family of transcription factors, along
with p45NF-E2, Nrf2, Nrf3, Bach1, and Bach2.33e35 Nrf1 is
expressed abundantly in mouse and human tissues and
upregulates expression of the antioxidant response ele-
ments (AREs) and subsequently cytoprotective genes,
playing an important role in preventing oxidative
stress.36,37 Relatively little had been known about Nrf1,
especially regarding its role in skin cancer and UVB
response. The role of Nrf1 in UVB-induced DNA damage
repair has begun to be unveiled in recent years. For the first
time, Han et al demonstrated that Nrf1 functions in cell
survival as well as NER upon UV damage in human kerati-
nocytes38 (Fig. 1). Loss of Nrf1 sensitized keratinocytes to
apoptosis with and without UVB-induced radiation via
upregulation of Bik but not other pro-apoptotic Bcl-2 family
members. A study in S. cerevisiae suggested that Nrf1 also
plays a role in proteasome homeostasis, which may be a
potential area of further investigation in regards to the
effect of Nrf1 on cell survival upon UVB irradiation.
Furthermore, Nrf1 is an essential player in the DNA repair
network that responds to UVB-induced damage. Nrf1
knockdown suppressed XPC mRNA and protein levels but
had no effect on other DNA repair proteins such as DDB1,
DDB2, and HR23B.38 We know that CPD but not 6-4 PP is the
principal culprit of skin tumorigenesis.39 Interestingly, Nrf1Fig. 1 Pathways that regulate XPC expression and activity in
UV-induced DNA repair.was shown to be important in the repair of CPD but not 6-4
PP, suggesting that its defect may be implicated in skin
cancer. Thus, Nrf1 functions as a regulator of XPC and plays
a crucial role in UV-induced NER in keratinocytes. Finally,
this study demonstrated a link between the role of Nrf1 in
antioxidant homeostasis and DNA repair, showing that Nrf1
regulates XPC expression through maintaining GSH levels.
The role of Nrf1 in DNA repair may play an important role in
the pathogenesis of SCC, as human epidermis with SCC
expressed less Nrf1 when compared unaffected epidermis
and Nrf1 expression was downregulated by UVB irradiation.
Taken together, Nrf1 demonstrates previously unrecognized
functions acts as a tumor suppressor that promotes cell
survival via Bik upregulation and DNA repair via enhance-
ment of XPC transcription.SIRT1
SIRT1 is a member of a highly conserved gene family (sir-
tuins) encoding nicotinamide adenine dinucleotide (NAD)
(þ)-dependent deacetylases, originally found to deacety-
late histones leading to increased DNA stability and pro-
longed survivaldgaining a reputation as a ‘longevity
protein’.40,41 Since then, SIRT1 has been found to deace-
tylate a multitude of protein targets involved in various
cellular pathways, including stress responses, apoptosis,
and axonal degeneration (Choi and Mostoslavsky, 2014).
Increasing evidence has suggested that SIRT1 has an
important role in UV signaling pathways. Cao et al found
that SIRT1 is expressed in human keratinocytes and is
downregulated by both UV and H2O2 in a JNK-dependent
manner.42 Activation of SIRT1 resulted in reduced UV- and
H2O2-induced p53 acetylation but increased AMP-activated
protein kinase (AMPK) and downstream acetyl-CoA
carboxylase (ACC) and phosphofructose kinase-2 (PFK-2)
phosphorylation. Moreover, SIRT1 deacetylates and de-
creases the function of the histone acetyltransferase TIP60,
such as autoacetylation and p53 acetylation, following UV
radiation.43 This may explain the previously reported
altered expression and function of TIP60 is altered in skin
tumors.44
SIRT1 is also essential for the regulation of GG-NER
(Fig. 1). Expression of SIRT1 is significantly reduced in skin
neoplasms associated with chronic sun exposure, including
actinic keratosis, SCC, and keratoacanthoma, SCC in situ,
and invasive SCC.45 Downregulation of SIRT1 significantly
sensitizes cells to UV irradiation.46 SIRT1 plays an essential
role in GG-NER via its effects on XPA and XPC upon UV
exposure. SIRT1 modulates the acetylation status of XPA46
and enhances the transcription of the key NER factor
XPC.45 The AKT pathway was shown to be essential for the
effect of SIRT1 on XPC. This is consistent with another
finding that SIRT1 deacetylates the tumor suppressor PTEN,
a known negative regulator for the PI3K/AKT pathway.47
Even as we outline the anti-tumor effects of SIRT1 and
its important role in DNA damage in response to UV radia-
tion here, the role of SIRT1 in cancer development is
complex and still under debate.48e50 Interestingly, SIRT1
has been shown to be both a tumor suppressor and an
oncogene in genetically modified mouse models. Mice with
whole body SIRT1 deletion did not affect chemical
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Ming et al aimed to reconcile this controversy by creating
mice with keratinocyte-specific SIRT1 deletion and then
monitoring UVB-induced tumor development.52 SIRT1
exerts opposite effects on skin tumorigenesis depending on
the gene dose. Heterozygous deletion of SIRT1 promoted
UVB tumorigenesis, whereas homozygous deletion sup-
pressed tumorigenesis but led to increased sensitivity to
chronic UVB injury and malignant conversion. Moreover,
SIRT1 was haploinsufficient for UVB-induced DNA damage
repair and XPC expression but only homozygous SIRT1
deletion increased p53 activation and UVB-induced
apoptosis in vivo. Heterozygous deletion had no such ef-
fect.52 Thus, the opposing views on the role of SIRT1 in
tumorigenesis can be explained by its gene dosage-
dependent differences in function as both an oncogene
and a tumor suppressor. Interestingly the SIRT1 activator
resveratrol reduces skin tumorigenesis induced by either
UVB or chemical carcinogens,51,53 suggesting that activating
SIRT1 reduces skin tumorigenesis.
AMPK
AMP-activated protein kinase is a well-conserved energy
sensor that plays a key role in the regulation of protein and
lipid metabolism in response to changes in fuel availabil-
ity.54 Although AMPK is traditionally thought to play a major
role in the regulation of cellular metabolism, it is now
widely recognized to have antineoplastic functions. The
AMPK pathway is down-regulated in human and mouse
SCCs, and its activators AICAR and metformin increase UVB-
induced DNA repair and XPC expression in mouse skin and in
normal human epidermal keratinocytes55 (Fig. 1). Further-
more, in UVB-damaged tumor-bearing mice, both topical
and systemic metformin prevented the formation of new
tumors and suppressed growth of established tumors,
demonstrating that AMPK acts as a tumor suppressor in the
skin by promoting DNA repair and controlling cell
proliferation.
DDB2/CUL4A/DDB1
The UV-damaged DNA-binding protein complex (UV-DDB) is
involved in the damage recognition step of NER (Fig. 1). UV-
DDB consists of two tightly associated subunits, DDB1 and
DDB2.56e58 UV-DDB exhibits very strong and specific binding
to UV-treated DNA and plays a role in GG-NER.59,60 Muta-
tions in the DDB2 gene account for the underlying defect in
XP-E. Sugasawa et al demonstrated that XPC undergoes
reversible ubiquitination upon UV radiation and that UV-
DDB activity was necessary for this.61 XPC and UV-DDB
physically interact and are polyubiquitinated by the UV-
DDB-ubiquitin ligase complex, leading to efficient NER.62e64
UV-induced inflammation: regulation and
crosstalk with UV-induced DNA repair
The observation that tumors arise in sites of chronic irri-
tation and inflammation dates back to 1828 and has stim-
ulated active research. Numerous animal models of UV-induced skin carcinogenesis have contributed to our
understanding of the multistage process of carcinogenesis
and shed insights in the differences between physiological
inflammation in wound healing and the deregulated tumor-
associated inflammation to skin cancer growth and pro-
gression. Rudolf Virchow first discovered the presence of
leukocytes within tumors in 1863 and concluded that a
functional connection exists between inflammation and
cancer. Over the past decades, in-depth investigations of
the molecular and cellular mechanisms mediating the
relationship between cancer and inflammation have flour-
ished. Classically, it was thought that the dynamic crosstalk
between immune cells and tumors resulted in the eradi-
cation of tumors. However, compelling evidence against
this theory has emerged, revealing the paradoxical role of
immune cells in tumor survival, proliferation, and dissem-
ination.65e69 UV-induced inflammatory responses lead to
increased blood flow and vascular permeability, resulting in
edema, erythema, hyperplastic responses, and activation
of cyclooxygenase-2 (COX-2) and prostaglandin (PG)
metabolites.70e72 Inflammation results in recruitment of
infiltrating leukocytes secreting a variety of proin-
flammatory cytokines at the UV-irradiated sites, and is
therefore considered an early event in tumor promotion.
Chronic inflammation plays a crucial role in all three stages
of tumor development: initiation, promotion, and pro-
gression.71 Various animal models and use of anti-
inflammatory agents as chemotherapy highlight the
importance of UV-induced inflammation in the develop-
ment and progression of skin tumors.73e76Nuclear factor-kappa B
Nuclear factor kappa B (NF-kB) is a dimeric transcription
factor composed of p50 and p65 Rel A family proteins that is
found in almost all cell types and plays a critical role in the
cellular stress response.77 In particular, NF-kB plays a key
role inflammation, cellular proliferation, and induction of
cancers. Constitutive upregulation of NF-kB has been
demonstrated in a variety of tumor cells.78e80 UVB radiation
results in the activation of IKKa, which phosphorylates and
degrades IkBa in epidermal keratinocytes.81 Interestingly,
UVB sequentially regulates the activities of different sub-
units of NF-kB82 (Fig. 2). While NF-kB/p50 is downregulated
in the early stage (6 h), NF-kB/p65 is upregulated in the
later stage (12 h). NF-kB is activated by UVB radiation and
contributes to UVB-induced skin carcinogenesis. Interest-
ingly, the early activation phase following UVB radiation has
been shown to occur through a non-canonical eIF-2
pathway. UVB radiation activates the uncoupling of consti-
tutive nitric oxide synthase (cNOS) in an eIF-2-dependent
manner.83 Recently, Tong and Wu reported that cNOS acti-
vation results in the activation of NF-kB following UVB ra-
diation. Continuous, but not acute, inhibition of cNOS with a
specific inhibitor led to suppression of IkB reduction and
subsequent NF-kB activation.84 Consequently, the NF-kB
signaling pathway has been a major target for the devel-
opment of alternative anti-cancer agents. Several groups
have demonstrated that epigallocatechin-3-gallate (EGCG),
the major constituent of green tea with significant anti-
inflammatory and cancer chemopreventive properties,
Fig. 2 UV-induced inflammation: regulation and crosstalk
with UV-induced DNA repair.
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and nuclear translocation of NF-kB leads to induction of pro-
inflammatory cytokines, such as IL-6 and TNF-a, both of
which are thought to play a role in the response to UVB
damage leading to apoptosis and inflammation.88e90
Cyclooxygenase
Accumulating evidence demonstrate that cyclooxygenases,
enzymes involved in prostaglandin synthesis, may be
involved in the pathogenesis of NMSC. There are two major
isoforms of cyclooxygenase, cyclooxygenase-1 (COX-1) and
cyclooxygenase-2 (COX-2). While COX-1 is constitutively
expressed in most cell types, COX-2 expression is induced by
a variety of stimuli. UV radiation is known to augment COX-2
expression in the human skin, and COX-2 is overexpressed in
chronically UVB-irradiated skin and UVB-induced SCCs91,92
(Fig. 2). COX-2, but not COX-1, is found to be involved in
increased susceptibility to SCCs.93,94 On the other hand,
both COX-1 and COX-2 appear to participate in the devel-
opment of BCCs. Multiple pathways have been demon-
strated to mediate UVB-induced COX-2 expression, including
AKT, p38, AMPK and SIRT6.95e97 This is further supported by
the findings that inhibiting p38a,98 AKT,99e101 or SIRT6,97 or
activating AMPK55,102 reduces skin tumorigenesis. Animals
that have been treated with pharmacological inhibitors of
COX-2 develop significantly fewer tumors upon UV radiation
compared with control mice. Recent studies suggest that
drugs that block COX-2 expression may prevent the devel-
opment of NMSCs and can be used as effective chemo-
preventive agents for NMSCs. Animal models also have
shown that both selective COX-2 inhibitor celecoxib and
nonselective COX-1 and COX-2 inhibitors, including nap-
roxen, indomethacin, and sulindac, can be used as effective
chemopreventive agents for UV-induced NMSCs.73,94,103,104
Moreover, phytochemicals such as proanthocyanidins have
shown association with reduced UV-induced skin tumors in
mice.105 Moreover, epidemiologic studies support that the
use of COX inhibitors (non-steroidal anti-inflammatory
drugs) is associated with decreased of NMSC.106,107 A case-
econtrol study in Australia reported that people who usedNSAIDs more than two times per week for at least a year had
a statistically significantly lower incidence of SCCs and
lower AK counts than those who had never used them or
used them infrequently.106 Another caseecontrol study in
Demark reported that the use of aspirin, nonselective
NSAIDs, and COX-2 inhibitors was associated with decreased
risk for SCC and melanoma.107
IL-12
Interleukin-12 (IL-12) is a pleiotropic cytokine involved in
inflammation composed of two subunits p35 and p40 and
has been shown to have antitumor activity in a wide variety
of tumor models.108,109 IL-12 possesses antitumor activity,
enhances antitumor immunity, and can repair ultraviolet
(UV)-induced DNA damage in the form of cyclobutane py-
rimidine dimers.110e113 The demonstration of its anti-tumor
effects in animal models has led to significant interest in
the therapeutic use of IL-12. A number of studies have
shown that IL-12p40-deficiency enhances skin carcinogen-
esis in mice in tumor incidence, tumor multiplicity, and the
extent of tumor angiogenesis114 (Fig. 2). Maeda et al111 and
Meeran et. al114 have shown that mice deficient in IL-12 are
at higher risk for UV radiation-induced skin tumors than
wild-type mice. Also, long-term exposure to UVB radiation
stimulates the phosphorylation of MAPK proteins in IL-12-
deficient mice to a greater extent than long-term UVB
exposure of WT mouse skin.115 Furthermore, Meeran
et al116 further elucidated the mechanism underlying the
antitumor effects of IL-12. Deficiency of IL-12 leads to
enhanced COX-2 expression and thus PGE2 production as
well as increased inflammatory cytokines such as IL-1b,
TNF-a, and IL-6. Reconstituting with recombinant IL-12
prior to UV exposure leads to decreased UVB-induced
leukocyte infiltration, reduced NF-kB activation, and
cyclin D expression, further substantiating the role of IL-12
in the inhibition of UV-induced skin tumorigenesis.115
HMGB1
Exposure to UV light induces inflammation independent of
microbial recognition, in which case endogenous signals are
activated to alert the body of the danger. These signals are
termed alarmins and represent a new class of inflammatory
mediators beginning to be recognized for their importance
in cutaneous inflammation. Classically, alarmins are intra-
cellular molecules that become released into the extra-
cellular milieu upon damage. When released, alarmins bind
pattern recognition receptors (PRRs) or other surface re-
ceptors, resulting in NF-kB activation and subsequent pro-
inflammatory cytokine production. High mobility group box-
1 (HMGB1) is an alarmin that has been extensively studied.
Normally localized to the nucleus, HMGB1 is released into
the cytoplasm and subsequently extracellularly to stimu-
late inflammation by binding to toll-like receptors (TLRs) or
receptor of advanced glycation end products (RAGE).117 A
recent study by Johnson and Wulff demonstrated that UV
radiation stimulated HMGB1 release in keratinocytes
in vitro and that HMGB1 is expressed in skin tumors after
chronic radiation118 (Fig. 2). This was supported by Bald
et al who showed that UV-induced inflammation promotes
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ated by the release of HMGB1 from UV-damaged keratino-
cytes and driven by TLR4.119 Together, these studies
suggest that HMGB1 plays a contributory role in UV-
mediated inflammation and tumor formation in both mel-
anoma and non-melanoma skin cancers.Toll-like receptors 2, 3, 4, 7, 8, 9
Toll-like receptors (TLRs) are a class of membrane-
spanning, non-catalytic receptors that recognize structur-
ally conserved microbial molecules and play a key role in
the inflammatory innate immune system. TLRs have
emerged as a major class of pattern recognition receptors
that initiate cutaneous immune responses and are
expressed on many different cell types in the skin,
including keratinocytes and Langerhans cells in the
epidermis. Not only do TLRs mediate responses to patho-
gens but also sterile inflammation triggered by endogenous
molecules. TLRs have achieved an extraordinary amount of
interest in cancer research due to their role in tumor pro-
gression. Recent literature show that activation of TLRs not
only leads to the upregulation of host defense mechanisms,
but also results in upregulation of DNA repair genes and
increased functional DNA repair, thus providing a link be-
tween inflammation and DNA damage.120 Several studies
have suggest that TLR2, 3, 4, 7, 8, and 9 may be involved in
DNA repair mechanisms induced by UVB radiation (Fig. 2).
In 2008, Zheng et al121 observed that activating TLR9 by
its ligand CpG DNA exhibited increased DNA repair rates
after irradiation in CD4þ T cells. Thereafter, a global gene
expression analysis revealed an increase in mouse splenic
mRNAs that code for proteins involved in DNA repair after
activation of TLR9 by CpGs.122 This was paralleled by
another study that showed upregulation of genes that
encode DNA repair molecules after intraperitoneal injec-
tion of CpG in mice.123
TLRs 7 and 8 are located in the endosome membrane and
recognize single-stranded RNAs.124 Imiquimod, TLR7 and
TLR8 agonist, is being widely used now as a topical thera-
peutic agent to treat dermatologic diseases such as HPV
infection, NMSC, and actinic keratosis.125e128 Animal studies
suggest that the mechanism by which Imiquimod exerts its
effects is by enhancing DNA repair gene expression as well
as functional repair of DNA damage mechanisms.129 More-
over, in vitro treatment of bone marrowederived cell lines
with Imiquimod leads to increased NER gene expression and
nuclear localization of the repair molecule, XPA.
While TLR4 was first recognized as a receptor for lipo-
polysaccharide from the cell wall of Gram-negative bacte-
ria, various non-microbial agonists such as taxol,
fibronectin, and heat shock proteins can bind and signal
through TLR4.130e133 Depending on the type of tumor,
polymorphisms in the TLR4 allele have been associated with
both susceptibility and resistance to cancer.134e137 Lewis
et al had suggested that TLR4 is required for UV-induced
immune suppression, showing that TLR4/ mice, when
compared with TLR4þ/þ mice, are resistant to UVB-
induced immunosuppression.138 To further substantiate
the basis of this finding, Ahmad et al investigated whether
DNA damage repair mechanism was involved. Specifically,XPA mRNA levels were significantly increased and less DNA
damage measured as CPDþ cells was evident in TLR4-
deficient mice after acute UVB exposure compared to
wild-type mice.139 Moreover, increased IL-12 and IL-23
production was observed in bone marrow-derived den-
dritic cells (BMDC) of UVB-exposed TLR4-deficient mice
compared to wild-type mice. Pre-UVB treatment of BMDCs
with anti-IL-12 and anti-IL-23 antibodies inhibited repair of
CPDs, with a concomitant decrease in XPA expression. Thus,
inhibiting TLR4 may be an approach to managing UVB-
induced cutaneous DNA damage and skin cancer.
A recent study revealed for the first time that a role for
TLR2 in mediating UVB-induced responses. When TLR2-
deficient mice were treated with repetitive UVB radiation,
they demonstrated less severe inflammatory responses
compared to the wild-type mice. UVB-induced expression
of heat-shock protein 70, an endogenous ligand of TLR2, as
well as UVB-induced IL-1b, IL6, and MMP-13 were lower in
TLR2-deficient mice.140 Further investigation is warranted
to delineate the specific mechanism underlying this finding.
TLR3 senses self-RNA released from necrotic keratino-
cytes following UV damage, and its activation in the skin
induces expression of the pro-inflammatory cytokines TNF-
a and IL-6.141 Bernard et al demonstrated that UV radiation
damages self noncoding RNA (U1 RNA), which is detected by
TLR3. Moreover, TLR3 was necessary for UVB radiation-
induced immune suppression using TLR3-deficient mice.142
This study provides a novel framework to understand the
UVB damage response, revealing the potential role for RNAs
as biomarkers of UVB-induced injury. This study can serve
as a platform to establish the role of TLR3 in UVB-induced
skin carcinogenesis.
ERBB2
UV radiation activates epidermal growth factors receptor
(EGFR) family members, including Erbb2 (human epithelial
growth factor receptor 2 (HER2)/neu). Erbb2 is a proto-
oncogene that is activated in many types of cancer and is
associated with aggressive and therapy-resistant disease.
Erbb2 is expressed in both follicular and epidermal kerati-
nocytes within the skin and plays many important func-
tions, including regulating inflammation, angiogenesis, cell
division, apoptosis, cell adhesion, and migration following
UV irradiation143 (Fig. 2). Inhibition or knockdown of Erbb2
suppresses UV-induced cell proliferation, cell survival, and
inflammation. In addition, Erbb2 was necessary for the
expression of NF-kB-regulated proinflammatory genes,
including IL-1b and COX-2. More recently, Rao et al
demonstrated that Erbb2 accelerates skin cancer progres-
sion via upregulation of ADAM12 (A Disintegrin And Metal-
loproteinase 12), suggesting a novel mechanism by which
Erbb2 contributes to the malignant progression of UV-
induced skin cancer. Inhibition of Erbb2 reduced tumor
burden, increased tumor regression, and delayed the pro-
gression of malignant SCC in UV-exposed mice.144
Cannabinoid receptor
Manipulation of the cannabinoid receptors has been useful
in pain management and treatment of cancer, and two
194 I. Kim, Y.-Y. Hecannabinoid receptors from mammalian tissues have been
cloned and characterized.145,146 Cannabinoid receptor 1
(CB1) is highly expressed in the brain, whereas the CB2
receptor is found mainly in the immune system. Until
recently, the function of CB1 and CB2 in cancer has
remained controversial. A study by Zheng
et al demonstrated that UV radiation directly activates CB1
and CB2 and that mice lacking both CB1 and CB2 are
resistant to UV-induced skin inflammation (Fig. 2). UVB
induced CB1/2 phosphorylation and internalization, acti-
vating TNF-a-mediated NF-kB activation. This was medi-
ated by the activation of ERK and JNK by UV radiation,
which was markedly reduced in CB1/2/ mouse embry-
onic fibroblasts (MEF). Using the two-stage skin carcino-
genesis mouse model in which skin papilloma are induced
by 7,12-dimethyl benz(a)anthracene (DMBA) and UVB radi-
ation, CB1/2/ mice developed smaller and less number
of skin papilloma compared to wild-type mice. This is the
first study to show that the CB1/2 receptors may enhance
the effect of DMBA/UVB-induced skin tumorigenesis,
demonstrating a novel function of these receptors in UV-
induced inflammation and cancer development.147Conclusion and perspective
Excess exposure to solar UVB radiation is a key risk factor
for skin cancer, resulting in DNA damage and inflammation.
Although skin carcinogenesis by DNA damage is considered a
predominant paradigm of UV toxicity, the role of inflam-
mation in UV-induced carcinogenesis has become an
established principle. In light of this, herein we highlight
the recent advances in two of these key molecular pro-
cesses that result in UV-mediated skin carcinogenesis: DNA
damage repair and inflammation. Understanding these
mechanisms will contribute to the development of more
effective chemopreventive tools in the control of UV-
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